KR900701320A - 호산구증다증을 억제시키거나 경감시키는 방법 - Google Patents

호산구증다증을 억제시키거나 경감시키는 방법

Info

Publication number
KR900701320A
KR900701320A KR1019900701417A KR900701417A KR900701320A KR 900701320 A KR900701320 A KR 900701320A KR 1019900701417 A KR1019900701417 A KR 1019900701417A KR 900701417 A KR900701417 A KR 900701417A KR 900701320 A KR900701320 A KR 900701320A
Authority
KR
South Korea
Prior art keywords
monoclonal antibody
fragment
human interleukin
antagonist
human
Prior art date
Application number
KR1019900701417A
Other languages
English (en)
Other versions
KR960002183B1 (ko
Inventor
엘. 코프멘 로버트
엠. 렌니크 도나
Original Assignee
스테이너 브이. 캔스태드
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900701320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 스테이너 브이. 캔스태드, 쉐링 코포레이션 filed Critical 스테이너 브이. 캔스태드
Publication of KR900701320A publication Critical patent/KR900701320A/ko
Application granted granted Critical
Publication of KR960002183B1 publication Critical patent/KR960002183B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

호산구증다증을 억제시키거나 경감시키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 차단된 IL-5모노클로날 항체로 치료한 기생충-감염된 마우스 및 차단된 IL-5모노클로날 항체로 치료하지 않는 기생층-감염된 마우스에서 호산구의 말초혈 수준에 대한 데이타 (층 백혈구에 대한%)률 나타내는 그래프이다.

Claims (6)

  1. 사람 인터루킨-5에 대한 유효량의 길항제를 투여함을 특징으로 하여 환자에게 호산구증다증을 억제시키거나 경감시키는 방법.
  2. 제1항에 있어서, 사람 인터루킨-5에 대한 길항제가 사람 인터루킨-7의 생물학적 활성을 차단시킬 수 있는 모노클로날 항체, 사람 인터루킨-5의 생물학적 활성운 차단시킨 수 있는 모노클로날 항체의 단편, 및 사람 인터루킨-5의 생물학적 활성을 차단시킬 수 있는 모노클로날 항체의 중쇄가변 영역 및 경쇄 가변 영역을 함유하는 결합 조성물중에서 선택되는 방법.
  3. 제2항에 있어서, 모노클로날 항체의 단편이 Fab단편인 방법.
  4. 제2항에 있어서, 모노클로날 항체가 사람-사람 하이브리도마에 의해 생성되는 단편.
  5. 제4항에 있어서, 모노클로날 항체의 단편이 Fab단편인 방법.
  6. 제2항에 있어서, 투여 단계가 일일 환자의 ㎏체중당 약 1내지 20㎎의 범위의 양의 길항제률 정맥내로 투여하는 단계를 추가로 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701417A 1988-11-03 1989-11-01 호산구증다증 억제또는 경감을 위한 약제학적 조성물 KR960002183B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03
US266,909 1988-11-03
PCT/US1989/004796 WO1990004979A2 (en) 1988-11-03 1989-11-01 Method of preventing or reducing eosinophilia

Publications (2)

Publication Number Publication Date
KR900701320A true KR900701320A (ko) 1990-12-01
KR960002183B1 KR960002183B1 (ko) 1996-02-13

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701417A KR960002183B1 (ko) 1988-11-03 1989-11-01 호산구증다증 억제또는 경감을 위한 약제학적 조성물

Country Status (17)

Country Link
EP (2) EP0367596B1 (ko)
JP (1) JPH07563B2 (ko)
KR (1) KR960002183B1 (ko)
AT (1) ATE98872T1 (ko)
AU (1) AU633034B2 (ko)
CA (1) CA2002144C (ko)
DE (1) DE68911653T2 (ko)
DK (1) DK81691D0 (ko)
ES (1) ES2062032T3 (ko)
HK (1) HK186196A (ko)
IE (1) IE63063B1 (ko)
IL (1) IL92180A (ko)
MY (1) MY107386A (ko)
NZ (1) NZ243939A (ko)
PH (1) PH26476A (ko)
WO (1) WO1990004979A2 (ko)
ZA (1) ZA898322B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683836B2 (en) * 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0681589A1 (en) * 1993-02-01 1995-11-15 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DE69535319T2 (de) * 1994-12-23 2007-07-19 Smithkline Beecham Corp. Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
MX2010010667A (es) 2008-03-28 2010-11-09 Glaxosmithkline Llc Metodos de tratamiento.
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854741T3 (de) * 1987-06-24 2002-08-14 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.

Also Published As

Publication number Publication date
IL92180A (en) 1997-04-15
EP0441891A1 (en) 1991-08-21
AU4644889A (en) 1990-05-28
CA2002144C (en) 2000-03-28
EP0367596B1 (en) 1993-12-22
HK186196A (en) 1996-10-11
DK81691A (da) 1991-05-02
NZ243939A (en) 1997-07-27
CA2002144A1 (en) 1990-05-03
MY107386A (en) 1995-11-30
ATE98872T1 (de) 1994-01-15
JPH07563B2 (ja) 1995-01-11
DE68911653D1 (de) 1994-02-10
IE63063B1 (en) 1995-03-22
KR960002183B1 (ko) 1996-02-13
DE68911653T2 (de) 1994-04-07
IL92180A0 (en) 1990-07-26
AU633034B2 (en) 1993-01-21
ES2062032T3 (es) 1994-12-16
IE893525L (en) 1990-05-03
WO1990004979A8 (en) 2005-06-16
ZA898322B (en) 1990-11-28
EP0367596A1 (en) 1990-05-09
DK81691D0 (da) 1991-05-02
PH26476A (en) 1992-07-27
JPH03505211A (ja) 1991-11-14
WO1990004979A2 (en) 1990-05-17

Similar Documents

Publication Publication Date Title
FI952327A0 (fi) Ihmisen B-lymfosyytteihin rajoittunutta erilaistumisantigeenia vastaan kimeeristen ja radioleimattujen vasta-aineiden terapeuttinen käyttö B-solulymfooman hoitoon
KR900701320A (ko) 호산구증다증을 억제시키거나 경감시키는 방법
DE69334259D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
KR900700132A (ko) 면역 글로불린 e 반응 억제 방법
NZ337072A (en) use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
ES2067600T3 (es) Procedimiento para la fabricacion de preparados de inmunoglobulina, que contienen igm y/o iga, no modificados de administracion intravenosa.
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
RU2004137823A (ru) Терапевтическое средство против гиперкальциемического криза
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
Greisman et al. The nature of endotoxin tolerance.
NO921883D0 (no) Protein-c-inneholdende legemiddel
ES2060695T3 (es) Concentrados terapeuticos de igm.
Dafny et al. Single injection of three different preparations of α-interferon modifies morphine abstinence signs for a prolonged period
Fischer Use of intravenous immune globulin in newborn infants.
KR890011572A (ko) 정신 기능을 증진시키는 방법
Prokopenko et al. Effect of the polyvalent proteinase inhibitor trasylol on antibody formation under normal conditions and in experimental atherosclerosis
Mansell et al. Comparative studies on dosages, routes of administration, and/or time course of anti-tumor effects of glucan, muramyl dipeptide (MDP), pyran (MVE), C. Parvum, and BCG
Jwo et al. FRACTIONATED SERA FROM SCHISTOSOMA-MANSONI INFECTED PATIENTS CONFERS PASSIVE PROTECTION IN MICE
Giuliani-Piccari et al. Recombinant interferon alfa-2b in chronic NANB hepatitis therapy: Results of three treatment schedules
Boleloucký et al. Neuroleptic therapy in neurotic states.
Gledhill Studies on the cimetidine resistant duodenal ulcer
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030116

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee